BRITANNIA TO DEVELOP NASAL POWDER FOR MIGRAINE SUFFERERS.
With DHE nasal powder, Britannia aims to offer a migraine treatment that not only works very quickly, but also for a longer time than most migraine treatments, helping prevent the common problem of migraines recurring. Historically, many pharmaceutical and biotechnology companies have avoided developing powders for nasal drug delivery because there is a perception that they can be irritating. Britannia has created a formula that is non-irritating, fast-acting, as bioavailable as subcutaneous injections and more stable than nasal liquid formulations.
"We are very enthusiastic about the potential for DHE nasal powder to make a significant difference in the lives of millions of migraine sufferers worldwide," said Max Noble, managing director of Britannia. "This product will provide relief from migraine pain very quickly and for longer than most medications -- huge benefits to those who are forced to miss days of work and life events because of their pain."
Migraine headaches have been called the most common neurological condition in the world and it is estimated that up to 20% of the world's population suffer from migraines. The World Health Organization recently recognized migraines among the world's top 20 leading causes of disability.
In the United States, according to the National Institute of Neurological Disorders and Stroke and National Headache Foundations, migraine headaches affect nearly 30 million Americans, disturbing 1 in 4 households, causing 157 million missed days of work, and costing American taxpayers $13 billion in missed work or reduced productivity each year. In the United Kingdom, the Migraine Action Association reports that 6 million people suffer migraines -- more than diabetes, asthma and epilepsy combined -- and migraines are responsible for the loss of more than 18 million working days each year and 750 million pounds in lost production.
In addition to DHE nasal powder for migraines and nasal powders for the treatment of Parkinson's disease and erectile dysfunction, Britannia has also developed a dry powder delivered via aerosol to prevent surgical adhesions and a respiratory powder for the treatment of asthma and other respiratory diseases.
About Britannia Pharmaceuticals
Founded in 1981 Britannia Pharmaceuticals Limited is a United Kingdom-based pharmaceutical firm whose mission is to become a leading supplier of innovative products for niche medical conditions. The company has pioneered new treatments for some of the world's most debilitating conditions including asthma, Parkinson's disease, drug addiction, erectile dysfunction and surgical adhesions. In addition to these treatments, Britannia has also developed nasal and respiratory drug delivery technologies that are applicable to a wide range of treatments. Britannia is a Forum Bioscience Company.
For more information, visit http://www.britannia-pharm.co.uk or call 617/443-9933, ext. 329.
|Printer friendly Cite/link Email Feedback|
|Date:||Dec 1, 2002|
|Previous Article:||MEDICURE EXPANDS INTELLECTUAL PROPERTY POSITION.|
|Next Article:||SEMBIOSYS GETS ALBERTA AWARD FOR PLANT BIOTECHNOLOGY.|